Table 5.

Proportion of patients with disease flare from week 12 to week 52—ad hoc patient-level data review following study completion (revised ITT population [completer analysis]^a)

	Sirukumab 100 mg q2w + 6-month prednisone (n = 9)	Sirukumab 100 mg q2w + 3-month prednisone (n = 5)	Sirukumab 50 mg q4w + 6-month prednisone (n = 5)	6-Month prednisone (n = 5)	12-Month prednisone (n = 4)
Number of patients with ≥ 1 flare, n (%)	1 (11.1)	1 (20.0)	1 (20.0)	4 (80.0)	2 (50.0)

ITT intent-to-treat, q2w every 2 weeks, q4w every 4 weeks

^aPatients in the revised ITT population who completed week 52 (N = 28)